In-Depth Analysis of the STYLE Trial: Defining the Therapeutic Boundaries and Clinical Role of Sunitinib as Second-Line Treatment for Type B3 Thymoma and Thymic Carcinoma

CHEN Cheng-yu; WANG Qian

doi:10.12019/j.issn.1671-5144.202511019

CHEN Cheng-yu, WANG Qian. In-Depth Analysis of the STYLE Trial: Defining the Therapeutic Boundaries and Clinical Role of Sunitinib as Second-Line Treatment for Type B3 Thymoma and Thymic CarcinomaJ. Journal of Evidence-Based Medicine, 2025, 25(5): 272-275. DOI: 10.12019/j.issn.1671-5144.202511019

Citation:

In-Depth Analysis of the STYLE Trial: Defining the Therapeutic Boundaries and Clinical Role of Sunitinib as Second-Line Treatment for Type B3 Thymoma and Thymic Carcinoma

No content published by the Journal of Evidence-Based Medicine may be reproduced or abridged without authorization. Please do not use or copy the layout and design of the journal without permission.

All articles published represent the opinions of the authors, and do not reflect the official policy of the Journal of Evidence-Based Medicine’ Sponsors or the Editorial Board, unless this is clearly specified.

Abstract

FullText(HTML)

References (14)

Cited By

Turn off MathJax

Article Contents

In-Depth Analysis of the STYLE Trial: Defining the Therapeutic Boundaries and Clinical Role of Sunitinib as Second-Line Treatment for Type B3 Thymoma and Thymic Carcinoma

Catalog

Export File

Citation

Format

Content